Business

Quanterix To Report Second Quarter 2024 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection,

articleQuanterix CorporationJuly 31, 20245/company/quanterix-corp/news/quanterix-to-report-second-quarter-2024-financial-results
Quanterix To Report Second Quarter 2024 Financial Results

About this update from Quanterix Corporation

[{"type":"text","content":" BILLERICA, Mass.--(BUSINESS WIRE)--\nQuanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 8, 2024 at 4:30 p.m. E.T., to discuss its second quarter 2024 financial results.\n\n\nQuanterix will issue a press release regarding the second quarter 2024 earnings prior to the conference call on Thursday, August 8, 2024 after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/.\n\n\nTo pre-register for the conference call with a webcast link click here and for an audio only link click here to obtain your dial-in number and passcode. Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at https://ir.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.\n\n\nAbout Quanterix\n\n\nFrom discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \"may,\" \"will,\" \"expect,\" \"plan,\" \"anticipate,\" \"estimate,\" \"intend\" and similar expressions (as well as other words or expressions referencing future events, conditions or circums...

More updates from Quanterix Corporation